02617.HK

Sep 21, 2026, 02:24 UTC

TransThera Sciences' self-developed multi-target small molecule kinase inhibitor tinengotinib (Jie'antai) was included in the Chinese Society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of biliary tract malignancies as a Class II recommendation, Category 2A, for advanced biliary tract cancer.